Lasofoxifene treatment of aromatase-resistant er+ cancer
AssigneeSermonix Pharmaceuticals, Inc.
InventorsBarry Samuel KOMM, Geoffrey L. GREENE
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in a patient who has progressed on an aromatase inhibitor. Of particular interest are ER+ cancers that do not harbor a gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene. The provided methods involve the administration of an effective amount of lasofoxifene, a pharmaceutically acceptable salt, prodrug or functional derivative thereof.
Claims1
A method of reducing the progression of estrogen receptor positive (ER+) cancer in a patient whose breast cancer has progressed on an aromatase inhibitor, wherein the cancer does not have a gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene, the method comprising:
- administering to the patient an effective amount of lasofoxifene or a pharmaceutically acceptable salt thereof
Dependencies are inferred from the claim text.